Baird Initiates Coverage On Enliven Therapeutics with Outperform Rating, Announces Price Target of $32
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Colleen Kusy has initiated coverage on Enliven Therapeutics (NASDAQ:ELVN) with an Outperform rating and set a price target of $32.
June 11, 2024 | 9:13 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Baird analyst Colleen Kusy has initiated coverage on Enliven Therapeutics with an Outperform rating and a price target of $32. This positive analyst rating and price target could boost investor confidence and potentially drive the stock price up in the short term.
The initiation of coverage with an Outperform rating and a specific price target of $32 by a reputable analyst can significantly influence investor sentiment. This positive outlook is likely to attract more investors, leading to a potential increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100